ConductScience.org, home

Paper3941019

Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.

Rubas W and 6 others. Int J Cancer, 1986. Cited by 59 papers, by iCite.

Cite this record

ConductScience Library. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Papers, record 3941019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3941019

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
PubMed
Journal
Int J Cancer
PubMed
Year
1986
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
59
iCite
Relative citation ratio, by iCite
2.27
iCite
Revised in PubMed
2019-07-08
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rubas WW
2Supersaxo AA
3Weder HGH G
4Hartmann HRH R
5Hengartner HH
6Schott HH
7Schwendener RR

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CytarabineMajor topic
Leukemia L1210Major topic
LiposomesMajor topic
MelanomaMajor topic
Animals
Bone Marrow
Female
Mice
Mice, Inbred C57BL
Mice, Inbred DBA

Source PubMed

Download CSV of topics

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 59 citations.

PMIDTitleJournalYearIn PapersSource
31015736A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.Acta Pharmacol Sin2019https://conductscience.org/library/papers/31015736PubMed
25469211Clinical potential of elacytarabine in patients with acute myeloid leukemia.Ther Adv Hematol2014https://conductscience.org/library/papers/25469211PubMed
20049941Delivery of therapeutic proteins.J Pharm Sci2010https://conductscience.org/library/papers/20049941PubMed
18385837Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids.Org Biomol Chem2008https://conductscience.org/library/papers/18385837PubMed
17614355Targeted pharmaceutical nanocarriers for cancer therapy and imaging.AAPS J2007https://conductscience.org/library/papers/17614355PubMed
12162758Clinical pharmacokinetics of cytarabine formulations.Clin Pharmacokinet2002https://conductscience.org/library/papers/12162758PubMed
10408395Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.Br J Cancer1999https://conductscience.org/library/papers/10408395PubMed
9083333Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.Br J Cancer1997https://conductscience.org/library/papers/9083333PubMed
8954169Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8954169PubMed
8576276Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8576276PubMed
7734320Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.Br J Cancer1995https://conductscience.org/library/papers/7734320PubMed
7554040Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7554040PubMed
3208792Incorporation of chlorpromazine into bilayer liposomes for protection against microsomal metabolism and liver absorption.Eur J Drug Metab Pharmacokinet1988https://conductscience.org/library/papers/3208792PubMed
2013113Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.Cancer Chemother Pharmacol1991https://conductscience.org/library/papers/2013113PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3941019

GET https://conductscience.org/api/papers/v1/3941019/authors